News - afatinib, Reproductive

Filter

Current filters:

afatinibReproductive

Popular Filters

51 to 75 of 90 results

Pfizer's Lyrica positive in two post-marketing studies

23-07-2012

Top-line results for global drugs behemoth Pfizer's already marketed diabetic nerve pain and post-herpetic…

LyricaNeurologicalPfizerPharmaceuticalReproductiveResearch

US FDA clears new ED drug Stendra

30-04-2012

The US Food and Drug Administration late Friday gave its approval for drug developer Vivus (Nasdaq: VVUS)…

avanafilMen's HealthNorth AmericaPharmaceuticalRegulationReproductiveStendraVivus

Bayer's Xarelto reimbursement backed in Canada; EMA concludes Yvidually arbitration

24-04-2012

The Canadian Agency for Drugs and Technologies in Health (CADTH) through the Common Drug Review (CDR),…

BayerCardio-vascularEuropeNorth AmericaPharmaceuticalPricingRegulationReproductiveXareltoYvidually

Bayer updates drospirenone-containing COCs labels to reflect VTE risk

11-04-2012

Following a further review of the products by the US Food and Drug Administration , Bayer HealthCare…

BayerBeyazdrospirenoneNorth AmericaPharmaceuticalRegulationReproductiveWomen's HealthYasminYaz

BioSante Pill-Plus improves sexual desire, arousal

20-03-2012

US drug developer BioSante Pharmaceuticals (Nasdaq: BPAX) says that data from studies of the Pill-Plus…

BioSante PharmaceuticalsLicensingPantarhei BiosciencePharmaceuticalPill-PlusReproductiveResearchWomen's Health

Apricus collaborates with Sandoz for ED drug

17-02-2012

San Diego, USA-based Apricus Biosciences (Nasdaq: APRI) said yesterday that its wholly-owned subsidiary…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalReproductiveSandozVitaros

Columbia Labs hands over NDA to Watson

13-02-2012

Columbia Laboratories (Nasdaq: CBRX) has transferred the New Drug Application for progesterone vaginal…

Columbia LaboratoriesCrinoneLicensingNorth AmericaPharmaceuticalRegulationReproductiveWatson PharmaceuticalsWomen's Health

Watson confirms patent challenge to Bayer’s Beyaz

13-02-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) on Friday confirmed that its subsidiary, Watson…

BayerBeyazGenericsNorth AmericaPatentsRegulationReproductiveWatson Pharmaceuticals

Watson settles with Janssen over Ortho Tri-Cyclen LO

08-02-2012

US generic drugmaker Watson Pharmaceutical (NYSE: WPI) says that its subsidiary, Watson Laboratories,…

GenericsJanssenJohnson & JohnsonLegalNorth AmericaPatentsReproductiveWatson PharmaceuticalsWomen's Health

FDA Advisory thumbs down for Columbia and Watson product

23-01-2012

US drugmakers Columbia Laboratories (Nasdaq: CBRX) and Watson Pharmaceuticals (NYSE: WPI) confirmed on…

Columbia LaboratoriesCrinoneNorth AmericaPharmaceuticalRegulationReproductiveWatson PharmaceuticalsWomen's Health

US ANDAs filed for generic Beyaz, Isentress and Epivir

12-01-2012

The US Food and Drug Administration says that Abbreviated New Drug Applications have been received by…

Anti-viralsBayerBeyazEpivirGenericsGlaxoSmithKlineIsentressMerck & CoPharmaceuticalRegulationReproductive

FDA panel mixed on Ortho Evra

12-12-2011

The majority of members of the US Food and Drug Administration’s Reproductive Health Drugs Advisory…

Johnson & JohnsonNorth AmericaOrtho EvraPharmaceuticalRegulationReproductiveWomen's Health

Mixed views on drospirenone OCs

09-12-2011

The majority of members of the US Food and Drug Administration’s Reproductive Health Drugs Advisory…

BayerDrospirenone and EstradiolNorth AmericaPharmaceuticalRegulationReproductiveWomen's HealthYasminYaz

Teva to continue selling Viagra generic in Russia

07-11-2011

Israel-basedTeva Pharmaceutical Industries (Nasdaq: TEVA) managed to avoid a high-profile confrontation…

DynamicoEuropeGenericsMarkets & MarketingPatentsPfizerPharmaceuticalReproductiveTeva Pharmaceutical IndustriesViagra

Lupin debuts generics of two Watson drugs, NOR-QD and Fortamet, in USA

16-10-2011

Indian drugmaker Lupin (500257. BY) last week revealed that it had launched generic versions in the USA…

DiabetesFortametGenericsLupinMarkets & MarketingNor-QDNorth AmericaPatentsReproductiveShionogiWatson Pharmaceuticals

Lilly’s Cialis meets endpoints in Ph III study in men with both erectile dysfunction and BPH

13-10-2011

US drug major Eli Lilly (NYSE: LLY) says that a pivotal Phase III study of its blockbuster erectile dysfunction…

CialisEli LillyPharmaceuticalReproductiveResearch

51 to 75 of 90 results

Back to top